Common use of Termination for Delay Clause in Contracts

Termination for Delay. In the event that SkyePharma has not received written notice that the FDA has: (a) accepted the Registration Application for DepoMorphine in the United States on or before September 1, 2004; or (b) finally approved the Registration of DepoMorphine in the United States with the Target Labeling on or before December 1, 2005; or (c) accepted the Registration Application for Propofol IDD-D in the United States on or before March 31, 2006; or (d) finally approved the Registration of Propofol IDD-D in the United States with the Target Labeling on or before June 1, 2007; then, in each case, Endo shall have the right to terminate its rights and obligations under this Agreement and all ancillary agreements related thereto by giving written notice to SkyePharma as provided in Section 11.9(i)(A).